Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen
European Journal of Neurology · 2024-10 · 31 (10)
DOI: 10.1111/ene.16393 ↗At a glance
Journal article in European Journal of Neurology, published online on 2024-06-26. Written by G Musso and 12 co-authors. Institution: Department of Medicine, University of Padova, Padova, Italy. Major MEDLINE topics: Neurofilament Proteins, Oligonucleotides, Profilins, Spinal Muscular Atrophies of Childhood. Cited 11 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fondazione Telethon.
Abstract (original language)
Background and Purpose The aim was to investigate whether neurofilament light chain (NfL) and profilin‐1 (PFN‐1) might qualify as surrogate disease and treatment‐response biomarkers by correlating their concentrations dynamic with clinical status in a cohort of 30 adult spinal muscular atrophy type 3 patients during nusinersen therapy up to 34 months.
Methods
Neurofilament light chain was measured in cerebrospinal fluid at each drug administration with a commercial enzyme‐linked immunosorbent assay (ELISA); PFN‐1 concentrations were tested in serum sampled at the same time points with commercial ELISA assays. Functional motor scores were evaluated at baseline, at the end of the loading phase and at each maintenance dose and correlated to biomarker levels. The concurrent effect of age and clinical phenotype was studied.
Results
Neurofilament light chain levels were included in the reference ranges at baseline; a significant increase was measured during loading phase until 1 month. PFN‐1 was higher at baseline than in controls and then decreased during therapy until reaching control levels. Age had an effect on NfL but not on PFN‐1. NfL was partially correlated to functional scores at baseline and at last time point, whilst no correlation was found for PFN‐1.
Conclusion
Cerebrospinal fluid NfL levels did not qualify as an optimal surrogate treatment biomarker in adult spinal muscular atrophy patients with a long disease duration, whilst PFN‐1 might to a greater extent represent lower motor neuron pathological processes. The observed biomarker level variation during the first 2 months of nusinersen treatment might suggest a limited effect on axonal remodeling or rearrangement.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, University of Padova, Padova, Italy.
- Laboratory Medicine, University-Hospital of Padova, Padova, Italy.
- Department of Neurosciences, University of Padova, Padova, Italy.
- Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, Italy.
ORCID profiles: G Musso, D Sabbatini, G Sorarù, E Pegoraro
Funding
- Fondazione Telethon
Cite
APA
Musso, G., Bello, L., Capece, G., Bozzoni, V., Caumo, L., Sabbatini, D., Zangaro, V., Sogus, E., Cosma, C., Petrosino, A., Sorarù, G., Plebani, M., & Pegoraro, E. (2024). Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen. European Journal of Neurology, 31(10). https://doi.org/10.1111/ene.16393
Vancouver
Musso G, Bello L, Capece G, Bozzoni V, Caumo L, Sabbatini D, et al. Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen. European Journal of Neurology. 2024;31(10). doi:10.1111/ene.16393
BibTeX
@article{Musso2024,
author = {Musso, G and Bello, L and Capece, G and Bozzoni, V and Caumo, L and Sabbatini, D and Zangaro, V and Sogus, E and Cosma, C and Petrosino, A and Sorarù, G and Plebani, M and Pegoraro, E},
title = {Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {10},
doi = {10.1111/ene.16393}
}
EUVIMED